Physical Health Management: Why it s important for adolescents and young adults in mental health services Early Intervention Service Wellington Lauren Heath and Erin Dawson
Introduction Second generation antipsychotic (SGAs) Research Shows EIS Client experiences Physical Health Guidelines Challenges Interventions
Why is metabolic monitoring x important? METABOLIC SYNDROME : Weight gain, dyslipidemia, hypertension, insulin resistance Cardiovascular disease, Diabetes Reduced life expectancy- 20%
Metabolic Highway (Stahl) Diabetes RIP Cardiovascular events Insulin resistance Prediabetes Appetite Obesity Dyslipidaemia
Why We Should Monitor? Mental Health clients tend to : Be less active Have a poor diet Come from a lower socio-economic status Smoke Less likely to access primary health
SGA HYPOTHESIS: Why weight gain???????????????????????????????
SGA HYPOTHESIS: Why weight gain??????????????????????????????? Histamine and Serotonin receptors appear to be involved
SGA HYPOTHESIS: Why weight gain??????????????????????????????? Histamine receptors in the hypothalamus- blocked leading to increased appetite Serotonin receptors- blocked in the gut, leading to loss of appetite suppression and inability to feel full i.e. Clozapine and olanzapine = highest incidence of weight gain of all SGAs.
EIS Client Experiences
Client Experience #1 22 year old Male of NZ descent. Olanzapine 10mg and Sodium Valporate 100mg Baseline Weight 61 kilograms. No baseline lipids done on ward. Two months later weight 70.9 kgs, 9.9 kgs. Cholesterol 5.5mmol/l, Triglyceride 1.7mmol/l, Cholesterol Ratio 3.8.
Client Experience #2 21 year old male Tokelauan descent. Olanzapine 40mg Baseline weight 133.6kgs, waist 130cm, BMI 40.1 Baseline Cholesterol 5.6, Triglycerides 1.06, chol ratio 2.25. Blood Glucose 5.2 Current weight 152.6 kg, 19kgs, BMI 46, Waist cms 139cm. Cholesterol 5.5, Triglycerides 0.6, Cholesterol Ratio 2.6, Blood Glucose 6.1
Wellington EIS: Physical Health Management Guidelines 2011 Baseline measurements Client s height, weight, waist circumference, BMI and BP, pulse Blood test baseline: fasting Glucose/HbA1c, electrolytes, liver function tests, thyroid function tests, fasting lipid panel, prolactin
Wellington EIS: Physical Health Management Guidelines 2011 At each monthly visit, then 3 monthly Weight, height, waist circumference, BP, BMI If weight gain or metabolic abnormalities: dietician referral, increase activity? Metformin? 3 monthly reviews at MDT 6 monthly audit- ongoing assessment
CCDHB Metabolic Monitoring: Primary/Secondary o Primary sector already screening clients. Secondary sector - slower uptake. Baseline screening Monthly for first three months for Olanzapine and Clozapine. Then quarterly for first year. All other Antipsychotics baseline screening then yearly.
Interventions -
Interventions Referral to dietitican Increase activity and groups Education re diet and healthy lifestyle Smoking cessation Change of Antipsychotic Medication. Metformin
Challenges Who does the monitoring? Staff motivated and committed to metabolic monitoring Engaging clients Decreased self confidence and being supported to try new things Time and transport
Successes for clients Clients independently playing sports and increasing activity Increased motivation and willingness Breaking the cycle of weight gain Persistence and Determination
Take home messages Someone on the team needs to take ownership of Metabolic Monitoring Its important to look for dyslipidemia, alongside weight, BMI and waist circumference. Assertive Follow up may lead to young people avoiding the metabolic highway.
References A New Zealand Mental health metabolic Working Group Initiative, proudly supported by Jannsen-Cilag Limited New Zealand. First edition published 2006. Second edition published 2008. Hetrick, S., Alvarez-Jimenez,M., Parker, A., Hughes, F., Willet, M., Morley, K., Fraser, R., McGorry, P.D, Thompson, A. (2010). Promoting physical health in youth mental health Services: Ensuring Routine monitoring of Weight and Metabolic Indices in a first Episode Psychosis Clinic. Australasian Psychiatry. 18:451-455. Metabolic Monitoring for people receiving Antipsychotic Therapy,, Capital Coast District Health Board, Wellington. Final Draft pending approval, March 2013. Meyer, J. M. & Stahl, S. M. (2009). The metabolic syndrome and schizophrenia. Acta Psychiatr Scand: 119: 4 14 National Institute for Health and Clinical Excellence. Guidelines for Schizophrenia (Clinical Guideline 82). NICE, 2006 (http://guidance.nice.org.uk/cg82/niceguidance/pdf/english). Stahl, S.M., Mignon, L., Meyer, J.M. (2009). Which comes first: atypical antipsychotic treatment or cardio metabolic risk? Acta Psychiatr Scand: 119: 171 179. Wu. R.R., Zhao, J.P., Guo, X.F., He, Y.Q., Fang, M.S., & Guo, W.B, et al. (2008a). Metformin addition attenuates olanzapine-induced weight gain in drug-naïve first-episode schizophrenia patients: a double-blind, placebo-controlled study. Am J Psychiatr 165:352 358. Wu, R.R., Zhao, J.P., Jin, H., Shao, P., Fang, M.S., Guo, X.F., et al. (2008b). Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA 299:185 193.
Questions?